SCLC
Amgen Secures Phase 3 Survival Data for Imdelltra in Small-Cell Lung Cancer, Strengthening Its Case for Full FDA Approval
Imdelltra, Amgen, Small-cell lung cancer (SCLC), Phase 3 trial, Overall survival, DLL3-targeting therapy, Immunotherapy, Biopharmaceuticals
Amgen’s Breakthrough Lung Cancer Drug Approved by FDA for Lethal and Challenging Subtype
Amgen, FDA, lung cancer, breakthrough drug, SCLC, small cell lung cancer, treatment, approval